Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099559 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL6077802 | 0.87 | L3MBTL1 (0.77) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18232439 | 0.85 | RAB9A (0.76) | SMN1; SMN2RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL24934740 | 0.85 | RAB9A (0.76) | SMN1; SMN2RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL8250757 | 0.85 | LMNA (0.65) | SMN1; SMN2RAB9AMEN1KMT2ALMNA | |
| SCHEMBL10099556 | 0.84 | RAB9A (0.75) | SMN1; SMN2RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL104431 | 0.84 | RAB9A (0.75) | SMN1; SMN2RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL8429875 | 0.83 | LMNA (0.70) | SMN1; SMN2RAB9AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL19630565 | 0.83 | EPHX2 (0.68) | SMN1; SMN2LMNAL3MBTL1EPHX2PPARG | |
| SCHEMBL10099594 | 0.83 | LMNA (0.70) | MEN1KMT2AALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | SMN1; SMN2 4581/4885RAB9A 3030/4885MEN1 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.